QIAGEN and GENCURIX, have announced a strategic partnership to jointly develop oncology assays for QIAGEN’s QIAcuityDx platform—a cutting-edge digital PCR system engineered for clinical diagnostics. This collaboration marks the launch of QIAGEN’s QIAcuityDx Partnering Program, positioning GENCURIX as its first development partner.
The partnership combines QIAGEN’s advanced QIAcuityDx digital PCR technology with GENCURIX’s expertise in multiplex assay development to create a new generation of sensitive, cost-effective oncology in vitro diagnostic (IVD) assays. These assays will serve both tissue and liquid biopsy applications, with flexible commercialization pathways and global distribution enabled through QIAGEN’s established Partnering Program.
Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN, emphasized the importance of this collaboration: “The QIAcuityDx Partnering Program is designed to create a diverse menu of IVD assays on the platform. Our first partnership with GENCURIX offers oncology customers high-quality diagnostics that complement existing methods like qPCR and next-generation sequencing (NGS). We are excited to collaborate and expand precision oncology testing worldwide.”
Sang Rae Cho, CEO of GENCURIX, echoed this sentiment: “Partnering with QIAGEN marks a pivotal moment for GENCURIX as we expand our molecular diagnostic technologies into the global market. The synergy between our assay development capabilities and QIAGEN’s powerful platform will deliver globally standardized precision cancer diagnostics.”
The QIAcuityDx Partnering Program invites third-party developers to create clinical assays for the QIAcuityDx system, part of QIAGEN’s broader QIAcuity family, which surpassed 2,700 cumulative placements by the end of 2024. The partnership builds on QIAGEN’s growing digital PCR ecosystem, which includes over 130 research assays launched in 2024 and a broad selection of custom assays available via the GeneGlobe platform.
As part of the agreement, GENCURIX will develop multiple oncology assays and lead the process for obtaining all necessary IVD regulatory approvals and certifications. Upon approval, these assays will be marketed globally through QIAGEN’s commercial infrastructure, ensuring seamless access for clinical laboratories worldwide.
By opening its platform to external developers, QIAGEN aims to address the increasing global demand for high-precision, cost-effective diagnostic tests. This inaugural collaboration with GENCURIX marks the first step in building a comprehensive, innovative assay portfolio for the QIAcuityDx platform—supported by QIAGEN’s global distribution network and technical expertise.